October 6, 2022
C-Path Awarded FDA Grant to Establish Public-Private Partnership to Advance Treatments for Rare Neurodegenerative Diseases: C-Path announced that it has recently launched a pre-consortium collaboration with the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER) and Center for Drug Evaluation and Research (CDER), focused on accelerating medical product development in alpha-1 antitrypsin deficiency (AATD). The FDA announced the pre-consortium today in a statement on its website.
